Treatment advances in colorectal cancers in 2019

doi:10.3877/cma.j.issn.2095-3224.2020.01.003

Abstract

Abstract:

In 2019, treatment advances in colorectal cancers were mainly in peri-operative settings as well as targeted agents and immunotherapy in palliative settings. This review briefly summarized these advances that might influence daily clinical practice based on reports from international meetings and high-quality articles published.

Key words: Colorectal neoplasms, Palliative care, Molecular targeted therapy, Immunotherapy, Treatment advances

Zhenghang Wang, Yanhao Li, Mifen Chen, Xicheng Wang, Lin Shen, Jian Li. Treatment advances in colorectal cancers in 2019[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2020, 09(01): 7-12.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2020.01.003

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2020/V09/I01/7

References 30

[1]	Seymour MT, Morton D. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer [J]. J Clin Oncol, 2019, 37 (Suppl_15): 3504.
[2]	Iveson T, Sobrero AF, Yoshino T, et al. Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC) [J]. J Clin Oncol, 2019, 37 (Suppl_15): 3501.
[3]	Yoshino T, Yamanaka T, Shiozawa M, et al. ACHIEVE-2 trial: A randomized phase III trial investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with high-risk stage II colon cancer (CC) [J]. Ann Oncol, 2019, 30 (Suppl_5): 525O.
[4]	Reinert T, Henriksen TV, Christensen E,et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer [J]. JAMA Oncol, 2019, doi: 10.1001/jamaoncol.2019.0528.
[5]	Tie J, Cohen JD, Wang Y, et al. Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer [J]. JAMA Oncol, 2019, doi: 10.1001/jamaoncol.2019.3616.
[6]	Wang Y, Li L, Cohen JD, et al. Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer [J]. JAMA Oncol, 2019, doi: 10.1001/jamaoncol.2019.0512.
[7]	Taieb J, Taly V, Vernerey D, et al. IDEA-FRANCEAnalysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration [J]. Ann Oncol, 2019, 30 (Suppl_5): LBA30_PR.
[8]	Le DT, Kim TW, Van Cutsem E,et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164 [J]. J Clin Oncol, 2020, 38: 1-9.
[9]	Schrock AB, Ouyang C, Sandhu J,et al. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer [J]. Ann Oncol, 2019, 30: 1096-1103.
[10]	Azad NS, Gray RJ, Overman MJ, et al. Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D-A subprotocol of the NCI-MATCH (EAY131) study [J]. J Clin Oncol, 2019, doi:10.1200/JCO.19.00818.
[11]	Cunningham D, Salazar R, Sobrero A, et al. Lefitolimod vs standard of care (SOC) for patients with metastatic colorectal cancer (mCRC) responding to first-line standard treatment: Results from the randomized phase III IMPALA trial [J]. Ann Oncol, 2019, 30 (Suppl_5): LBA33.
[12]	Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603) [J]. J Clin Oncol, 2019, 37 (Suppl_15): 2522.
[13]	Chen EX, Jonker DJ, Loree JM, et al. CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC) [J]. J Clin Oncol, 2019, 37 (Suppl_15): 3512.
[14]	Sastre J, Vieitez JM, Gomez-España MA, et al. Randomized phase III study comparing FOLFOX+bevacizumab versus folfoxiri + bevacizumab (BEV) as 1st line treatment in patients with metastatic colorectal cancer (mCRC) with ≥3 baseline circulating tumor cells (bCTCs) [J]. J Clin Oncol, 2019, 37 (Suppl_15): 3507.
[15]	Cremolini C, Antoniotti C, Lonardi S, et al. Updated results of TRIBE2, a phase III, randomized strategy study by GONO in the first-and second-line treatment of unresectable mCRC [J]. J Clin Oncol, 2019, 37 (Suppl_15): 3508.
[16]	Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer [J]. N Engl J Med, 2019, 381: 1632-1643.
[17]	Tabernero T, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab with or without binimetinib for BRAF V600E-mutant metastatic colorectal cancer: Expanded results from a randomized, 3-arm, phase III study vs the choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC)[J]. Ann Oncol, 2019, 30 (Suppl_5): LBA32.
[18]	Laurent-Puig P, Pekin D, Normand C,et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy[J]. Clin Cancer Res, 2015, 21: 1087-1097.
[19]	Santos C, Azuara D, Vieitez JM, et al. Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial [J]. Ann Oncol, 2019, 30: 796-803.
[20]	Vidal J, Bellosillo B, Santos Vivas C, et al. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy [J]. Ann Oncol, 2019, 30: 439-446.
[21]	Valladares-Ayerbes M, García-Alfonso P, Muñoz Luengo J, et al. Sequential RAS mutation testing in cfDNA in RAS wild type (wt) metastatic colorectal cancer (mCRC) patients (pt) treated with panitumumab (P) and chemotherapy (CT) in first-line (1L): PERSEIDA study [J]. Ann Oncol, 2019, 30 (Suppl_5): 531PD.
[22]	Morano F, Corallo S, Lonardi S, et al. RAS negative hyperselection of patients with and wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy [J]. J Clin Oncol, 2019, 37: 3099-3110.
[23]	Xu J, Liu T, Tang W, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as first-line treatment for patients with RAS mutant unresectable colorectal liver-limited metastases: A single center randomized control trial [J]. Ann Oncol, 2019, 30 (Suppl_5): LBA31.
[24]	Govindan R, Fakih MG, Price TJ, et al. Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours [J]. Ann Oncol, 2019, 30 (Suppl_5): 446PD.
[25]	Janne PA, Papadopoulos K, Ou I, et al. A phase 1 clinical trial evaluating the pharmacokinetics (PK), safety, and clinical activity of MRTX849, a mutant-selective small molecule KRAS G12C inhibitor, in advanced solid tumors[EB/OL]. (2019-10-28)[2019-12-31]. URL
[26]	高静，孙志伟，李艳艳,等. 中国结直肠癌患者966例中KRAS和BRAF基因突变分析[J]. 中华病理学杂志, 2012, 41: 579-583.
[27]	Wiesweg M, Kasper S, Worm K,et al. Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer [J]. Oncogene, 2018, 38: 2953-2966.
[28]	Saffarian A, Mulet C, Regnault B, et al. Crypt- and Mucosa-Associated Core Microbiotas in Humans and Their Alteration in Colon Cancer Patients [J]. mBio, 2019, 10: e01315-01319.
[29]	Yuan L, Zhang S, Li H, et al. The influence of gut microbiota dysbiosis to the efficacy of 5-Fluorouracil treatment on colorectal cancer [J]. Biomed Pharmacother, 2018, 108: 184-193.
[30]	Aarnoutse R, Ziemons J, Penders J, et al. The clinical link between human intestinal microbiota and systemic cancer therapy [J]. Int J Mol Sci, 2019, 20: 4145.

Please choose a citation manager

Content to export